Leuprolide Acetate for Puberty Suppression in Transgender and Gender Diverse Youth: A Comparison of Subcutaneous Eligard Versus Intramuscular Lupron



      To compare the efficacy of intramuscular Lupron and subcutaneous Eligard, two formulations of leuprolide, for puberty suppression in transgender and gender diverse (TGD) youth.


      A retrospective chart review of TGD youth receiving Lupron or Eligard 22.5 mg every 3 months was conducted to determine hormone levels obtained 1 hour after an injection (1hrPost) and patient-reported clinical puberty suppression.


      Forty eight patients were analyzed: 33% assigned female at birth of which 25% were premenarchal, mean age at first injection 13.7 years, and 50% received concurrent gender affirming hormones. Of these, 13% received Lupron, 52% Eligard, and 35% initially received Lupron then transitioned to Eligard due to drug shortages. There were 55 incidents of 1hrPost levels, 42 after Eligard and 13 after Lupron. Clinical puberty suppression occurred in all patients; however, biochemical suppression occurred in 90% of Eligard and 69% of Lupron (p = .06).


      Eligard and Lupron were both effective in suppressing clinical puberty progression in our population of TGD youth, of which 50% were receiving concurrent gender affirming hormones.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Adolescent Health
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Johns M.M.
        • Lowry R.
        • Andrzejewski J.
        • et al.
        Transgender identity and experiences of violence victimization, substance use, suicide risk, and sexual risk behaviors among high school students - 19 states and Large Urban School Districts, 2017.
        MMWR Morb Mortal Wkly Rep. 2019; 68: 67-71
        • Rew L.
        • Young C.C.
        • Monge M.
        • Bogucka R.
        Review: Puberty blockers for transgender and gender diverse youth-a critical review of the literature.
        Child Adolesc Ment Health. 2021; 26: 3-14
        • Hembree W.C.
        • Cohen-Kettenis P.T.
        • Gooren L.
        • et al.
        Endocrine treatment of gender-Dysphoric/gender-incongruent Persons: An Endocrine Society clinical practice Guideline [published correction appears in J Clin Endocrinol Metab. 2018;103:699] [published correction appears in J Clin Endocrinol Metab. 2018 Jul 1;103(7):2758-2759].
        J Clin Endocrinol Metab. 2017; 102: 3869-3903
        • World Professional Association for Transgender Health
        Standards of care for the health of transsexual, transgender, and gender nonconforming people [7th Version].
        (Available at:)
        Date: 2012
        Date accessed: November 25, 2021
        • Bangalore Krishna K.
        • Fuqua J.S.
        • Rogol A.D.
        • et al.
        Use of gonadotropin-releasing hormone analogs in children: Update by an international consortium.
        Horm Res Paediatr. 2019; 91: 357-372
        • Braeckman J.
        • Michielsen D.
        Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(®)/Depo-Eligard(®)) for advanced prostate cancer in daily practice: A Belgian prospective non-interventional study.
        Arch Med Sci. 2014; 10: 477-483
        • Bhatia S.
        • Neely E.K.
        • Wilson D.M.
        Serum luteinizing hormone rises within minutes after depot leuprolide injection: Implications for monitoring therapy.
        Pediatrics. 2002; 109: E30
        • Houk C.P.
        • Kunselman A.R.
        • Lee P.A.
        The diagnostic value of a brief GnRH analogue stimulation test in girls with central precocious puberty: A single 30-minute post-stimulation LH sample is adequate.
        J Pediatr Endocrinol Metab. 2008; 21: 1113-1118
        • Mericq V.
        • Lammoglia J.J.
        • Unanue N.
        • et al.
        Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: Preliminary results.
        Clin Endocrinol (Oxf). 2009; 71: 686-690
        • Brito V.N.
        • Latronico A.C.
        • Arnhold I.J.
        • Mendonca B.B.
        A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls.
        J Clin Endocrinol Metab. 2004; 89: 4338-4342
        • Lee P.A.
        • Klein K.
        • Mauras N.
        • et al.
        36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty.
        J Clin Endocrinol Metab. 2014; 99: 3153-3159
        • Stevens J.
        • Gomez-Lobo V.
        • Pine-Twaddell E.
        Insurance coverage of puberty blocker therapies for transgender youth.
        Pediatrics. 2015; 136: 1029-1031
        • Fuld K.
        • Chi C.
        • Neely E.K.
        A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty.
        J Pediatr. 2011; 159: 982-987.e1
      1. Lexicomp. (n.d.). Leuprolide: Drug information. UpToDate.
        (Available at:)
        • T'Sjoen G.
        • Arcelus J.
        • Gooren L.
        • et al.
        Endocrinology of transgender medicine.
        Endocr Rev. 2019; 40: 97-117